192 related articles for article (PubMed ID: 12771704)
1. The management of high risk prostate cancer.
Akduman B; Crawford ED
J Urol; 2003 Jun; 169(6):1993-8. PubMed ID: 12771704
[TBL] [Abstract][Full Text] [Related]
2. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
3. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
[TBL] [Abstract][Full Text] [Related]
5. The case for adjuvant therapy for prostate cancer.
Glodé LM
J Urol; 2006 Dec; 176(6 Pt 2):S30-3. PubMed ID: 17084163
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
7. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review.
Pasquier D; Ballereau C
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):972-9. PubMed ID: 18954710
[TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
10. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy.
Kibel AS; Nelson JB
Prostate Cancer Prostatic Dis; 2007; 10(2):119-26. PubMed ID: 17310261
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
King CR; Presti JC; Gill H; Brooks J; Hancock SL
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
[TBL] [Abstract][Full Text] [Related]
13. Radiation therapy after radical prostatectomy: a review of the issues and options.
Valicenti RK; Gomella LG; Perez CA
Semin Radiat Oncol; 2003 Apr; 13(2):130-40. PubMed ID: 12728442
[TBL] [Abstract][Full Text] [Related]
14. PSA relapse prostate cancer: the importance of tailored therapy.
Aranha O; Vaishampayan U
Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer update: 2007.
Lin AM; Small EJ
Curr Opin Oncol; 2008 May; 20(3):294-9. PubMed ID: 18391629
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen recurrence after definitive therapy.
Freedland SJ; Moul JW
J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant total androgen suppression and radiotherapy in the management of locally advanced prostate cancer.
Roach M
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):32-7; discussion 38. PubMed ID: 8725889
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
19. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
20. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
